Complete Cost Breakdown: Cancer Treatment in India 2026
Complete Cost Breakdown: Cancer Treatment in India 2026
Research consistently shows that cost transparency is the single most important factor in medical tourism decisions. Patients who understand what treatment will cost — before they book a flight — are far more likely to follow through with appropriate care. Yet oncology cost information for international patients remains frustratingly opaque. Indian hospitals quote packages, not itemised costs. Insurance intermediaries add complexity. Hidden costs surprise families mid-treatment.
This guide presents the most complete 2026 cost breakdown for cancer treatment in India available to international patients. Every figure is drawn from current hospital pricing and independent patient reports, with no hospital commission or promotional pricing.
Why India's Cancer Treatment Costs Are Lower
Before the numbers, the mechanism matters. India's oncology cost advantage is not the result of lower quality or corner-cutting. It comes from structural economic differences:
Labour costs: Indian oncologists earn 15–25% of their USA counterparts. Indian nurses and technicians earn even less proportionally. Staff costs represent 35–50% of hospital operating expenses.
Land and infrastructure: Hospital construction and land costs in India are 5–10x lower than the USA or UK. Debt service on hospital facilities is dramatically lower.
Generic pharmaceuticals: India is the world's largest generic pharmaceutical manufacturer. Targeted cancer drugs that cost $8,000–15,000 per month in the USA are available as generics in India for $200–800 per month.
Regulatory efficiency: Indian hospitals operate with significantly lower administrative overhead than US hospitals, where billing, compliance, and insurance administration add 25–30% to the cost of care.
The equipment and protocols are identical. The surgical instruments, radiation machines, and chemotherapy drugs at Apollo or Fortis are the same manufacturers as at MD Anderson or Johns Hopkins.
Chemotherapy Costs in India: Per-Cycle Breakdown
Chemotherapy costs vary by drug regimen. Below are common oncology regimens with India pricing for the drug cost and administration:
| Regimen | Cancer Type | India (per cycle) | USA (per cycle) |
|---|---|---|---|
| AC-T (doxorubicin + cyclophosphamide, then paclitaxel) | Breast | $400–800 | $3,000–8,000 |
| FOLFOX (folinic acid + fluorouracil + oxaliplatin) | Colorectal | $300–600 | $2,000–5,000 |
| Carboplatin + Paclitaxel | Ovarian, Lung | $350–700 | $2,500–6,000 |
| CHOP (cyclophosphamide + doxorubicin + vincristine + prednisolone) | Lymphoma | $500–900 | $3,500–9,000 |
| Gemcitabine + Cisplatin | Pancreatic, Bladder | $250–500 | $1,500–4,000 |
| Pembrolizumab (Keytruda) | Multiple | $800–1,500 | $12,000–18,000 |
| Trastuzumab (Herceptin biosimilar) | Breast (HER2+) | $200–400 | $3,000–7,000 |
Administration fees at Indian hospitals add $100–250 per infusion cycle. Most chemotherapy cycles are repeated every 3–4 weeks; a 6-cycle regimen costs approximately $2,400–5,400 in drug and administration costs in India.
Radiation Therapy Costs in India 2026
Radiation technology significantly affects cost. India's major cancer centres have all modalities:
| Radiation Type | Indication | India (full course) | USA (full course) |
|---|---|---|---|
| 3D Conformal RT | Standard solid tumours | $3,000–6,000 | $30,000–50,000 |
| IMRT (Intensity Modulated RT) | Prostate, head/neck, gynaecological | $5,000–9,000 | $50,000–80,000 |
| IGRT (Image Guided RT) | Any with motion concern | $6,000–10,000 | $55,000–90,000 |
| SBRT/SRS (Stereotactic Body/Radiosurgery) | Lung oligomets, brain mets | $4,000–8,000 | $25,000–50,000 |
| Proton Beam Therapy | Paediatric, brain, prostate | $25,000–40,000 | $100,000–180,000 |
India has proton beam therapy at Apollo Proton Cancer Centre (Chennai) and Manipal Hospitals (Bangalore) — among only a handful of proton centres in Asia.
Cancer Surgery Costs in India
Surgery costs depend primarily on complexity, operative time, and whether laparoscopic or open approach is used. Major cancer surgeries at Indian private hospitals:
| Surgery | India | USA |
|---|---|---|
| Mastectomy (total) | $4,000–7,000 | $20,000–45,000 |
| Lumpectomy + sentinel node biopsy | $2,500–4,500 | $12,000–25,000 |
| Colectomy (laparoscopic) | $5,000–8,000 | $25,000–60,000 |
| Whipple procedure (pancreaticoduodenectomy) | $9,000–15,000 | $45,000–100,000 |
| Nephrectomy (radical, laparoscopic) | $5,000–8,000 | $20,000–50,000 |
| Lung lobectomy (VATS) | $6,000–10,000 | $30,000–80,000 |
| Thyroidectomy | $2,500–4,000 | $10,000–25,000 |
| Cystectomy (radical) | $7,000–12,000 | $35,000–75,000 |
| Prostatectomy (robotic) | $6,000–10,000 | $20,000–50,000 |
| Craniotomy for brain tumour | $8,000–15,000 | $50,000–150,000 |
Total Package Costs by Cancer Type
For patients seeking an all-inclusive treatment estimate, the following ranges cover the complete treatment course — surgery, chemotherapy, and/or radiation as indicated for each cancer type. These are hospital package estimates, not drug-cost-only figures:
| Cancer | Stage | India (total treatment) | USA (total treatment) |
|---|---|---|---|
| Breast cancer (early, ER+) | I–II | $12,000–20,000 | $100,000–200,000 |
| Breast cancer (HER2+, requiring trastuzumab) | II–III | $18,000–28,000 | $200,000–400,000 |
| Colorectal cancer | II–III | $15,000–25,000 | $100,000–200,000 |
| Lung cancer (NSCLC, resectable) | I–II | $15,000–28,000 | $100,000–250,000 |
| Lung cancer (with targeted therapy) | III–IV | $20,000–35,000 | $200,000–500,000 |
| Prostate cancer (robotic surgery + radiation) | I–II | $10,000–18,000 | $80,000–150,000 |
| Cervical cancer | II | $12,000–20,000 | $80,000–150,000 |
| Lymphoma (DLBCL, R-CHOP) | I–II | $15,000–25,000 | $80,000–200,000 |
| Leukaemia (AML, induction + consolidation) | — | $20,000–40,000 | $200,000–400,000 |
| Bone marrow transplant (autologous) | — | $25,000–35,000 | $100,000–200,000 |
Targeted Therapy and Immunotherapy: India's Generics Advantage
This is where India's cost advantage is most dramatic. Targeted cancer drugs in their branded form cost $8,000–20,000 per month in the USA. India manufactures generics that the CDSCO has approved at 5–15% of originator prices.
Key available generics in India:
- Imatinib (Gleevec) — generic: $80–150/month vs $5,000+ USA
- Gefitinib (Iressa) — generic: $100–200/month vs $5,000+ USA
- Erlotinib (Tarceva) — generic: $100–250/month vs $5,000+ USA
- Sorafenib (Nexavar) — generic: $200–400/month vs $8,000+ USA
- Lenalidomide (Revlimid) — generic: $300–600/month vs $15,000+ USA
Immunotherapy biosimilars (bevacizumab, trastuzumab) are widely available in India at $200–800 per infusion versus $3,000–7,000 per infusion for originator products in the USA.
Hidden Costs to Budget For
Hospital package quotes do not include everything. International patients should budget separately for:
Pre-treatment evaluation: $500–1,500 for consultations, biopsy, and staging investigations not included in the treatment package.
Accommodation: $25–80 per night near hospital for patients and companions, for the full treatment duration.
Meals: $20–40 per day for patient and companion.
Medications during recovery: $100–400 per month for supportive medications (anti-nausea, pain, growth factors) not always included in packages.
Visa extensions: If treatment extends beyond 90 days, Indian medical visa extensions cost $30–50. Arodya assists with extension documentation.
Return flights: Factor in business class if you are flying post-operatively or during active chemotherapy. Economy on long-haul flights post-surgery is not advisable for the first 4–6 weeks.
Comparing Hospitals on Cost and Quality
Not all Indian hospitals charge the same, and cost differences between hospitals are not straightforward indicators of quality.
Government hospitals (AIIMS, Tata Memorial Mumbai): Subsidised pricing significantly below private hospitals for equivalent or superior oncology outcomes. Longer wait times; less international patient infrastructure.
Major private networks (Apollo, Fortis, Max, Medanta): Mid-to-premium pricing, strong international patient services, JCI accreditation, and well-documented outcomes.
Tier 2 city hospitals (Hyderabad, Pune, Ahmedabad): 15–25% lower costs than Delhi/Mumbai with comparable oncology expertise at leading centres. Worth considering for patients primarily seeking cost optimisation.
Arodya's hospital selection process reviews your specific cancer type and stage against each hospital's oncology outcomes data, not just package pricing. We negotiate directly with hospitals on your behalf and ensure the quote covers what you actually need.
The Bottom Line on Cancer Treatment Costs
India's cancer treatment cost advantage is 75–90% compared to the USA for most common cancer types and treatment modalities. This is not a marketing figure — it reflects the structural economic realities of Indian healthcare that are not going to change.
For African patients facing cancer diagnoses, the choice is often not between India and the USA. It is between India and inadequate care at home. India's oncology infrastructure — JCI-accredited hospitals, board-certified oncologists, IMRT radiation, robotic surgery, and generic targeted therapies — represents a realistic path to the same standard of cancer care that patients in the USA and UK receive, at a price that African families can manage.
Cost transparency is the first step. Start with your diagnosis and request a cost estimate from Arodya. We provide itemised estimates within 48 hours.
